Journal
MARROW
Volume 1364, Issue -, Pages 62-73Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12750
Keywords
PTH; LRP6; Sost; osteocyte; MEF2; HDAC; sclerostin
Categories
Funding
- NIDDK NIH HHS [DK083350, R01 DK083350] Funding Source: Medline
Ask authors/readers for more resources
Parathyroid hormone (PTH) suppresses the expression of the bone formation inhibitor sclerostin (Sost) inosteocytes by inducing nuclear accumulation of histone deacetylases (HDACs) to inhibit themyocyte enhancer factor 2 (MEF2)-dependent Sost bone enhancer. Previous studies revealed that lipoprotein receptor-related protein 6 (LRP6) mediates the intracellular signaling activation and the anabolic bone effect of PTH. Here, we investigated whether LRP6 mediates the inhibitory effect of PTH on Sost using an osteoblast-specific Lrp6-knockout (LRP6-KO) mouse model. An increased level of Sost mRNA expression was detected in femur tissue from LRP6-KO mice, compared to wild-type littermates. The number of osteocytes expressing sclerostin protein was also increased in bone tissue of LRP6-KO littermates, indicating a negative regulatory role of LRP6 on Sost/sclerostin. In wild-type littermates, intermittent PTH treatment significantly suppressed Sost mRNA expression in bone and the number of sclerostin(+) osteocytes, while the effect of PTH was much less significant in LRP6-KO mice. Additionally, PTH-induced downregulation of MEF2C and 2D, as well as HDAC changes in osteocytes, were abrogated in LRP6-KO mice. These data indicate that LRP6 is required for PTH suppression of Sost expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available